undamentalytics Newsletter
Sign in

China Pharma Holdings, Inc. (CPHI) stock

Add to watchlist

Add holding +

NYSE: CPHI NYSE Pharmaceuticals

D Fundamentals grade

China Pharma Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: free cash flow after stock pay is not positive. How we value companies.

China Pharma Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds6 adding, 1 cuttingOf 2 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter China Pharma Holdings files

Where China Pharma stands after its latest 10-Q

China Pharma has little or no product revenue yet; it used $2m of cash in the twelve months to June 2026. That puts it 45 of 51 for growth among the pharmaceuticals companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 3 financial-health checks.

Our models give no value for China Pharma Holdings at present, so past values are not shown.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

China Pharma Holdings, Inc.'s trailing-twelve-month revenue fell 11.0% year on year, with a free-cash-flow margin of -49.2%. Where it stands out: days sales outstanding of 17 days ranks 3 of 59 pharmaceuticals companies we cover. Where it lags: gross margin of 11.8% ranks 56 of 59 pharmaceuticals companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 225% year over year while revenue fell 11% — the balance sheet is expanding 236 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in China Pharma Holdings, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 11.0% over the last 12 months.
  • Loss-making. Operating margin is -111.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 27.9 points on a year ago.
  • Burning cash. Free cash flow was -49.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 6.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 808% and a beta of 5.0 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
$40.00 against an average estimate of $60.00: missed by 33.3%
Revenue
$1m, down 7.5% on a year earlier

China Pharma Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.6%
  • 1 week-3.2%
  • 1 month-7.6%
  • This year-49.6%
  • 1 year-62.8%
  • 5 years-99.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.9M
Operating margin
-111.8%
Net margin
-114.3%
EPS (TTM, diluted)
$-1.41

Growth

Revenue growth
−11.0%
Change in growth rate
−3.9 pts

Cash

Free cash flow (TTM)
-$1.9M
FCF margin
-49.2%

Earnings

Last results
March 31, 2017

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

China Pharma Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

Valuation models

We value China Pharma Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — 0 Does not apply: no positive value
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare China Pharma Holdings, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$80.00$130.00$90.00$130.00$120.00$225.00$240.00$50.00$6.00$2.30$1.21
Market value$1.7bn$2.8bn$2.0bn$2.8bn$2.6bn$4.9bn$5.5bn$26m$10m$4m$5m
+ Net debt (− = net cash)−$2m−$3m$7m$5m$3m$6m$5m$9m$2m$2m$3m
Enterprise value$1.7bn$2.8bn$2.0bn$2.8bn$2.6bn$4.9bn$5.5bn$35m$12m$6m$8m
Multiples
Price / sales 85.7x181.9x148.4xn/mn/mn/mn/m3.2x1.4x0.9x1.3x
Price / earnings ———————————
Price / free cash flow n/mn/mn/mn/mn/m—————58.4x
EV / EBITDA —————n/mn/m—n/m——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

26 /100

Weak moat

How hard China Pharma Holdings's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -22.8% of total assets over 10 years.

  • Pricing power 0 / 20

    Gross margin has been a median 10.0%, moving by 16.0 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -75.6%; its worst year was -181.1%.

  • Cash conversion 12 / 20

    Free cash flow was positive in 8 of 10 years, at a median 7.0% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 263.5% over five years; stock-based pay has been a median 0.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for China Pharma Holdings, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2011 $60.00 $40.00 −33.3%
Mar 2011 $57.50 $50.00 −13.0%
Dec 2010 $78.33 $95.00 +21.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.6%
of tradable shares
Days to cover
0.05
at average volume
Short interest, 1 month
+9%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
89.6%
of shares
Employees
215
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CPHI+7%−79%−88%−62%−47%−50%
Industry peers (median)−20%−49%−13%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CPHI42%8%25%33%25%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CPHI−68%−82%−93%−73%−58%−93%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from February 17, 2021 to May 4, 2026. Getting back needed a 122977% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.52 – $8.10
From 52-week high
−92.5%
vs 50-day average
−18.6%
vs 200-day average
−26.1%
Volatility (1 year)
808%
Beta vs S&P 500
4.98

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 1 down
typical move ±3.8%
After a week
0 up, 1 down
typical move ±0.0%
After a month
0 up, 1 down
typical move ±7.7%
Results releasedNext dayS&P 500 next day5 days21 days
March 31, 2017 −3.8% −0.4% 0.0% −7.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

China Pharma Holdings, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) China Pharma Holdings, Inc.
$3M $4M $5M $6M $7M $8M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $7.8M Revenue (TTM), FY23 Q4: $7M Revenue (TTM), FY24 Q1: $6.4M Revenue (TTM), FY24 Q2: $6.2M Revenue (TTM), FY24 Q3: $5.5M Revenue (TTM), FY24 Q4: $4.5M Revenue (TTM), FY25 Q1: $4.3M Revenue (TTM), FY25 Q2: $4.4M Revenue (TTM), FY25 Q3: $4.1M Revenue (TTM), FY25 Q4: $4.1M Revenue (TTM), FY26 Q1: $4M Revenue (TTM), FY26 Q2: $3.9M $3.9M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $7.8M
FY23 Q4 $7M
FY24 Q1 $6.4M
FY24 Q2 $6.2M
FY24 Q3 $5.5M
FY24 Q4 $4.5M
FY25 Q1 $4.3M
FY25 Q2 $4.4M
FY25 Q3 $4.1M
FY25 Q4 $4.1M
FY26 Q1 $4M
FY26 Q2 $3.9M
Revenue growth, TTM YoY China Pharma Holdings, Inc.
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -3.6% Revenue growth, TTM YoY, FY23 Q4: -13.5% Revenue growth, TTM YoY, FY24 Q1: -24.1% Revenue growth, TTM YoY, FY24 Q2: -21.4% Revenue growth, TTM YoY, FY24 Q3: -28.8% Revenue growth, TTM YoY, FY24 Q4: -35.4% Revenue growth, TTM YoY, FY25 Q1: -33.1% Revenue growth, TTM YoY, FY25 Q2: -29.6% Revenue growth, TTM YoY, FY25 Q3: -26.9% Revenue growth, TTM YoY, FY25 Q4: -8.5% Revenue growth, TTM YoY, FY26 Q1: -7.1% Revenue growth, TTM YoY, FY26 Q2: -11.0% -11.0%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -3.6%
FY23 Q4 -13.5%
FY24 Q1 -24.1%
FY24 Q2 -21.4%
FY24 Q3 -28.8%
FY24 Q4 -35.4%
FY25 Q1 -33.1%
FY25 Q2 -29.6%
FY25 Q3 -26.9%
FY25 Q4 -8.5%
FY26 Q1 -7.1%
FY26 Q2 -11.0%
Operating margin (TTM) China Pharma Holdings, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -35.2% Operating margin (TTM), FY23 Q4: -39.2% Operating margin (TTM), FY24 Q1: -50.9% Operating margin (TTM), FY24 Q2: -67.3% Operating margin (TTM), FY24 Q3: -82.6% Operating margin (TTM), FY24 Q4: -101.3% Operating margin (TTM), FY25 Q1: -103.2% Operating margin (TTM), FY25 Q2: -84.0% Operating margin (TTM), FY25 Q3: -79.8% Operating margin (TTM), FY25 Q4: -78.2% Operating margin (TTM), FY26 Q1: -90.1% Operating margin (TTM), FY26 Q2: -111.8% -111.8%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -35.2%
FY23 Q4 -39.2%
FY24 Q1 -50.9%
FY24 Q2 -67.3%
FY24 Q3 -82.6%
FY24 Q4 -101.3%
FY25 Q1 -103.2%
FY25 Q2 -84.0%
FY25 Q3 -79.8%
FY25 Q4 -78.2%
FY26 Q1 -90.1%
FY26 Q2 -111.8%
FCF margin (TTM) China Pharma Holdings, Inc.
-60% -40% -20% 0% 20% FY20 Q1 FY20 Q4 FY22 Q4 FY26 Q2 FCF margin (TTM), FY20 Q1: 2.0% FCF margin (TTM), FY20 Q2: -5.5% FCF margin (TTM), FY20 Q3: -14.1% FCF margin (TTM), FY20 Q4: -8.4% FCF margin (TTM), FY22 Q2: -30.5% FCF margin (TTM), FY22 Q3: -20.2% FCF margin (TTM), FY22 Q4: -10.0% FCF margin (TTM), FY25 Q2: 8.7% FCF margin (TTM), FY25 Q3: 5.3% FCF margin (TTM), FY25 Q4: 2.1% FCF margin (TTM), FY26 Q1: -40.9% FCF margin (TTM), FY26 Q2: -49.2% -49.2%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY20 Q1 2.0%
FY20 Q2 -5.5%
FY20 Q3 -14.1%
FY20 Q4 -8.4%
FY22 Q2 -30.5%
FY22 Q3 -20.2%
FY22 Q4 -10.0%
FY25 Q2 8.7%
FY25 Q3 5.3%
FY25 Q4 2.1%
FY26 Q1 -40.9%
FY26 Q2 -49.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 74 81 55 33 22 20 16 13 12 11 11 10 8 7 5 4 4
Gross profit 30 29 14 −0 3 1 3 2 2 1 2 0 −0 −0 −2 −0 0
EBITDA 26 23 7 −17 −37 −11 −5 −15 −7 −17 0 0 −1 0 −2 −2 −3
Operating income 25 22 6 −19 −39 −14 −8 −19 −10 −20 −3 −3 −4 −3 −5 −3 −4
Net income 23 19 5 −20 −40 −15 −9 −19 −11 −21 −3 −3 −4 −3 −5 −3 −4
Diluted EPS $1.08 $0.88 $11.00 −$0.92 −$1.82 −$0.70 −$21.00 −$44.00 −$25.00 −$48.00 −$7.00 −$74.00 −$7.56 −$1.82 −$2.71 −$0.74 —
Growth (year on year)
Revenue — +9.1% −32.8% −39.8% −32.5% −8.1% −23.5% −15.1% −6.7% −11.4% −0.5% −11.3% −15.9% −13.5% −35.4% −8.5% −11.0%
EBITDA — −11.3% −68.2% −330.6% — — — — — — — — −473.3% — — — —
Operating income — −10.7% −73.2% −415.1% — — — — — — — — — — — — —
Net income — −17.7% −76.0% −533.3% — — — — — — — — — — — — —
Diluted EPS — −18.5% +>999% −108.4% — — — — — — — — — — — — —
Margins
Gross margin 40.7% 35.7% 25.8% −1.5% 12.1% 7.2% 20.7% 18.7% 16.0% 13.6% 18.0% 3.6% −6.1% −4.0% −43.8% −3.2% 11.8%
EBITDA margin 35.2% 28.6% 13.5% −51.8% −167.0% −52.6% −32.6% −116.5% −58.3% −160.0% 0.9% 2.4% −10.5% 0.0% −43.5% −41.9% −66.2%
Operating margin 33.2% 27.1% 10.8% −56.7% −175.1% −70.3% −52.4% −141.4% −84.7% −186.8% −23.7% −29.7% −43.8% −39.2% −101.3% −78.2% −111.8%
Net margin 31.5% 23.7% 8.5% −61.0% −178.7% −75.7% −59.0% −145.9% −87.2% −189.5% −26.4% −35.3% −49.0% −43.9% −104.6% −76.9% −114.3%
Free-cash-flow margin 10.6% 6.9% 7.0% 83.5% 4.6% 19.8% 17.4% 5.3% 14.8% 4.3% −8.4% −7.1% −10.0% −10.1% −9.8% 2.1% −3.6%
Cash flow
Cash from operations 8 5 4 9 6 3 3 1 2 1 −0 −0 −0 −1 −0 0 −0
Capital spending −0 −0 −0 −19 5 −1 0 0 0 0 1 0 0 0 0 0 0
Free cash flow 8 6 4 27 1 4 3 1 2 0 −1 −1 −1 −1 −0 0 −0
Stock-based pay 0 0 0 0 — — — — — — — — — — — — —
Free cash flow after stock pay 8 5 4 27 — — — — — — — — — — — — —
Balance sheet
Cash 4 4 4 — — 6 3 2 1 1 1 5 2 1 1 0 0
Total debt 4 4 5 5 5 5 0 9 7 4 7 10 11 3 3 3 —
Net debt (negative = net cash) 0 −0 1 — — −2 −3 7 5 3 6 5 9 2 2 3 −0
Diluted shares — 22m 22m — 22m 22m 22m 22m 22m 22m 22m 23m — 2m 2m 4m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $45m
Short-term assets $2mLonger-term assets $43m
What it owes, and who funded it · $45m
Short-term liabilities $8mLonger-term liabilities $1mShareholders' equity $36m
  • Short-term assets cover short-term liabilities $2m of assets due within a year against $8m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $2m short-term assets against $847,021 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$4m against $32,068 of interest.

From China Pharma Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
8.5%
of revenue
Days sales outstanding
17 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated CPHI TXMD EYPT NTRB LPCN SXTC Median
Revenue, last 12 months $4m $3m $3m $2m $2m $1m $276m
Revenue growth, last 12 months −11.0% 27.8% −94.6% −37.3% −62.7% −34.6% 9.9%
Revenue growth, 3-year average −21.0% −63.9% −57.9% −10.8% 205.6% — 5.5%
Revenue growth, latest quarter −7.5% −8.7% −90.5% −29.7% −69.5% — 6.5%
Gross margin 11.8% 100.0% — 33.1% — 21.9% 62.0%
Operating margin −111.8% −120.9% <−999% −435.6% −800.8% −625.9% −5.9%
Operating margin, 3-year average −87.7% −334.1% <−999% −396.6% −378.5% −267.4% −7.4%
Net margin −114.3% −6.6% <−999% −430.4% −755.1% −545.2% −7.3%
Cash from operations / revenue −3.6% 94.7% <−999% −224.5% −713.0% −353.0% 10.2%
Free-cash-flow margin −49.2% 94.7% <−999% −224.5% −713.0% −353.0% 8.6%
Free-cash-flow margin, 3-year average −16.3% −281.8% <−999% −217.5% −309.9% −126.6% 7.4%
Stock pay / revenue 0.7% 1.7% >999% 65.9% 14.6% 466.2% 3.6%
Change in share count 6.8% 18.0% 4.2% 8.9% 25.2% >999% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -11.0% 10.0% 61 of 74
Change in growth rate Growth -3.9pp -0.3pp 49 of 74
Gross margin Profitability 11.8% 59.8% 56 of 59
Operating margin Profitability -111.8% -5.9% 56 of 67
Net margin Profitability -114.3% -7.3% 62 of 75
Free-cash-flow margin Cash generation -49.2% 10.1% 62 of 74
Days sales outstanding Balance sheet 17 days 72 days 3 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$134,530
Institutions reporting
8
Shares held vs prior quarter
▲ 690.9%
Positions opened / closed
3 / 1

Top buyers and sellers, Q2 2026: 6 institutions bought and 1 sold ; the biggest buyer was Citadel Advisors LLC (+113K shares) and the biggest seller Citigroup Inc (−996). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Citadel Advisors LLC $82,806 125K 61.6% ▲ 870.6%
Two Sigma Securities, LLC $23,543 36K 17.5% New
Renaissance Technologies LLC $9,931 15K 7.4% ▲ 31.8%
Jane Street Group, LLC $9,167 14K 6.8% New
Ground Swell Capital, LLC $7,004 11K 5.2% New
UBS Group AG $2,052 3K 1.5% ▲ 699.2%
Efg International AG $26 0K 0.0% 0.0%
Danske Bank A/S $1 0K 0.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not China Pharma Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • March 31, 2017
  • February 28, 2008
  • September 21, 2006

Recent SEC filings

Data status

When each part of this page on China Pharma Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

China Pharma Holdings, Inc. in brief

What does China Pharma Holdings, Inc. do?
China Pharma Holdings, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is China Pharma Holdings, Inc.'s stock ticker?
China Pharma Holdings, Inc. trades under the ticker CPHI on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is China Pharma Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, China Pharma Holdings, Inc. reported revenue of $3.9M, 11.0% lower than a year earlier, according to its SEC filings.
What is China Pharma Holdings, Inc.'s free cash flow?
China Pharma Holdings, Inc.'s free-cash-flow margin is -49.2% of revenue over the trailing twelve months, ranking 62 of the 74 pharmaceuticals companies we cover.
Who are China Pharma Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Citadel Advisors LLC, Two Sigma Securities, LLC and Renaissance Technologies LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is China Pharma Holdings, Inc.'s market cap?
On December 31, 2025, China Pharma Holdings, Inc.'s market capitalisation was about $5.2M and net debt of $3M. Market figures come from third-party market data and may be delayed.
Who are China Pharma Holdings, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to China Pharma Holdings, Inc. are Therapeuticsmd, Inc., Eyepoint, Inc., Nutriband Inc., Lipocine Inc. and China SXT Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against China Pharma Holdings, Inc.'s.